Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 120; no. 11; p. e2220272120
• Main Authors: G. Moreira, Thais, Gauthier, Christian D., Murphy, Liam, Lanser, Toby B., Paul, Anu, Matos, Kimble T. F., Mangani, Davide, Izzy, Saef, Rezende, Rafael M., Healy, Brian C., Baecher-Allan, Clare M., Chitnis, Tanuja, Kuchroo, Vijay, Weiner, Howard L.
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 14.03.2023
• Subjects: Administration, Intranasal; Animals; Antibodies, Monoclonal - therapeutic use; Biological Sciences; C-reactive protein; CCL4 protein; CD3 antigen; Coronaviruses; COVID-19; Effector cells; Gene expression; Gene sequencing; GTP-Binding Proteins; Humans; Inflammation; Inflammatory response; Interleukin 6; Intranasal administration; Lymphocytes; Lymphocytes B; Lymphocytes T; Membrane Proteins; Mice; Monoclonal antibodies; Monocytes; Proteomics; Respiratory diseases; rho-Associated Kinases; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; T-Lymphocytes; Transcriptomics; Transforming Growth Factor beta1 - genetics; Transforming growth factor-b1; Viral diseases; COVID-19; anti-CD3; SARS-CoV-2; Foralumab; T cells

T cells are present in early stages of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and play a major role in disease outcome and long-lasting immunity. Nasal administration of a fully human anti-CD3 monoclonal antibody (Foralumab) reduced lung inflammation as well as se...